Empagliflozin and metformin to reduce cardiac risk in type 2 diabetes?

Type 2 diabetes is a major risk factor for cardiovascular disease. Having both type 2 diabetes and cardiovascular disease increases…

The challenge of diabetes management in LMICs

In low-and middle-income countries, especially in Sub-Saharan Africa, noncommunicable diseases (NCDs) such as diabetes are placing a growing strain on…

Read More
CPD POINTS: 1

Achieving optimal glycaemic control with insulin lispro pens

A rise in body weight or worsening insulin tolerance in diabetic patients nearly always results in an increase in their…

Read More
CPD POINTS: 1

New hope for obesity patients

Liraglutide, which has consistently shown 5%-10% of weight-loss when combined with diet and physical activity, has been given the go-ahead…

Read More
CPD POINTS: 3

T2DM management simplified

Type 2 diabetes (T2DM) has attained the status of a global pandemic, spreading from affluent industrialised nations to emerging economies…

Osteoporosis an overlooked disease in diabetes

Over the past few years, evidence shows that people with diabetes are at extremely high risk of osteoporosis and fracture.…

Could dulaglutide reduce the T2DM burden?

Let’s face it, with public health crises popping up out of nowhere lately, the last thing the healthcare system needs…

Read More
CPD POINTS: 1

Changing the diabetes paradigm

Figures from 2019 indicate that one in 11 adults (20-79 years) – or an estimated 463 million people worldwide have…

Dulaglutide is an ‘engineering feat’ in T2DM treatment

The goal of type 2 diabetes (T2DM) treatment is not only to promote glucose lowering, but also to prevent glycaemic…

Lowering glucose, preventing glycaemic variability equally important in T2DM treatment

The goal of type 2 diabetes (T2DM) treatment is not only to promote glucose lowering, but also to prevent glycaemic…

Read More
CPD POINTS: 2

Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30

Approximately 1.6 billion people worldwide are Muslims. Ramadan is the ninth month of the Islamic calendar, and fasting (total abstinence…

Basal insulin in patients who fast during Ramadan

A real-world study has evaluated a second-generation basal insulin used alongside IDF-DAR guidelines. The results contrast with literature reports of…

Diabetes and COVID-19

How do we manage diabetic patients in an age of COVID-19, given the increased risk of mortality experienced by diabetic…

Read More
CPD POINTS: 1

T2DM epidemic: Can we turn the tide?

Diabetes is the most common endocrine disorder diagnosed worldwide.  The cause of type 1 diabetes (T1DM) – previously known as…

Guidelines: managing diabetes in older adults

About 6% of the South African population – about 3.5 million people – suffer from diabetes, and 5 million more…

Skin can show first signs of diabetes

Certain skin conditions commonly seen in dermatology practice, can often be the first signs that a patient has diabetes, said…

Medical Chronicle August 2019 CPDs

These are both CPDs produced for the August 2019 issue of Medical Chronicle, accredited for 3 points. This month’s CPDs…

Cardiovascular risk reduction in diabetes mellitus

Globally significant increase in the prevalence of diabetes has been documented and this increase is expected to impact in a…

Immune cell linked to type 1 diabetes

A research team from Johns Hopkins Medicine has been the first to document the existence of the long searched-for ‘X…

Insulin pens: what do patients prefer?

The use of pens as the preferred means of insulin delivery has become standard over the course of the last…

Read More
CPD POINTS: 1
« » page 1 / 2